Filter
114
Filtered Results: 114
Text search:
S.
Swaminathan
Featured
Recommendations
13
New Publications
15
Language
Document type
No document type
64
Studies & Reports
16
Videos
12
Guidelines
10
Manuals
6
Fact sheets
3
Resource Platforms
2
Infographics
1
Countries / Regions
India
31
Kenya
3
Brazil
3
Nepal
2
China
2
Mozambique
2
Global
2
Asia
2
Latin America and the Carribbean
2
Middle East and North Africa
2
South–East Asia Region
2
Russia
2
Angola
2
Indonesia
2
North Korea
1
Colombia
1
Timor Leste/ East Timor
1
Thailand
1
Ukraine
1
Syria
1
Nigeria
1
Malawi
1
Malaysia
1
Guinea-Bissau
1
Tanzania
1
West and Central Africa
1
Japan
1
Portugal
1
Spain
1
East and Southern Africa
1
Bangladesh
1
South Africa
1
Vietnam
1
Eastern Europe
1
Sri Lanka
1
Ethiopia
1
Bhutan
1
South Sudan
1
Myanmar / Burma
1
Authors & Publishers
Publication Years
Category
Countries
38
Clinical Guidelines
13
Public Health
5
Key Resources
2
Women & Child Health
1
Toolboxes
COVID-19
26
TB
25
HIV
8
NTDs
5
Planetary Health
3
Ebola & Marburg
2
Caregiver
2
NCDs
2
AMR
2
Mental Health
1
Refugee
1
Natural Hazards
1
Health Financing Toolbox
1
Global Health Education
1
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5 http://www.biomedcentral.com/1471-2334/14/S1/S5
La presente guía tiene además como objetivo, ser un respaldo y no una camisa de fuerza para los médicos, pues pretendemos con ella proveer evidencia sólida respecto a los riesgos, beneficios o consecuencias que puede generar la toma de una decisión en pacientes con tuberculosis. Como lo propone...
Review Article:
The American Journal of the Medical Sciences 2011;341(6):493–498.]
Lancet Public Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/ S2468-2667(18)30138-5
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Глобальными приоритетами для лечения туберкулеза (ТБ) и борьбы с ним являются улучшенное и ранее выявление случаев туберкулеза, в том числе случаев заболевания с о...
These guidelines are applicable to all biomedical, social and behavioural science research for health conducted in India involving human participants, their biological material and data.
The purpose of such research should be: i. directed towards enhancing knowledge about the human condition while ...
Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to elimina...
Sub-Saharan African Journal of Medicine: Year : 2014 | Volume : 1 | Issue : 1 | Page : 1-14
O currículo irá ajudá-lo, a si e à sua comunidade, a compreender a ciência do vírus que causa a COVID-19 e outros vírus como este. Ajudá-lo-á a descobrir como este vírus o está a afectar ou a afectar ou poderá vir a afectá-lo no futuro. Ajudá-lo-á a compreender as acções que pode to...
Lancet Glob Health 2018, Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30387-5
International Journal of Infectious Diseases 32 (2015) 170–178
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ß 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:...
PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018
Policy statement.
Lancet Glob Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30407-8
This Interim Guidance outlines how key public health and social measures needed to reduce the risk of COVID-19 spread and the impact of the disease can be adapted for use in low capacity and humanitarian settings. The recommendations outlined here need to be adjusted to the scale of transmission, co...
WHO Living guideline: Drugs to prevent COVID-19
recommended
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform...
